MA52571A - Anticorps bispécifiques ayant des étiquettes appairées à des charges c-terminales clivables - Google Patents

Anticorps bispécifiques ayant des étiquettes appairées à des charges c-terminales clivables

Info

Publication number
MA52571A
MA52571A MA052571A MA52571A MA52571A MA 52571 A MA52571 A MA 52571A MA 052571 A MA052571 A MA 052571A MA 52571 A MA52571 A MA 52571A MA 52571 A MA52571 A MA 52571A
Authority
MA
Morocco
Prior art keywords
clivable
bispecific antibodies
terminal loads
labels matched
labels
Prior art date
Application number
MA052571A
Other languages
English (en)
French (fr)
Inventor
Neeraj J Agrawal
Kevin Graham
Alex W Jacobitz
John K Kawooya
Ray Lieh Yoon Low
Christopher Mohr
Dante ROMANINI
Stephen Smith
Oliver Thiel
Victoria Wagner
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA52571A publication Critical patent/MA52571A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA052571A 2018-05-08 2019-05-08 Anticorps bispécifiques ayant des étiquettes appairées à des charges c-terminales clivables MA52571A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862668626P 2018-05-08 2018-05-08

Publications (1)

Publication Number Publication Date
MA52571A true MA52571A (fr) 2021-03-17

Family

ID=66676901

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052571A MA52571A (fr) 2018-05-08 2019-05-08 Anticorps bispécifiques ayant des étiquettes appairées à des charges c-terminales clivables

Country Status (8)

Country Link
US (2) US12384849B2 (https=)
EP (1) EP3790904A1 (https=)
JP (3) JP2021523101A (https=)
AU (2) AU2019265699B2 (https=)
CA (1) CA3099450A1 (https=)
MA (1) MA52571A (https=)
MX (2) MX2020011844A (https=)
WO (1) WO2019217587A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020304671A1 (en) * 2019-06-28 2022-01-20 Amgen Inc. Anti-CGRP receptor/anti-PAC1 receptor bispecific antigen binding proteins
EP4466020A4 (en) * 2022-01-21 2026-04-15 Lyvgen Biopharma Holdings Ltd Multi-specific antibodies and their uses in avidity receptor cross-linking and immune modulation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US7101692B2 (en) * 1999-04-15 2006-09-05 The Regents Of The University Of California Identification of sortase gene
WO2001000814A2 (en) * 1999-06-25 2001-01-04 Universität Zürich Hetero-associating coiled-coil peptides and screenign method therefor
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US20050214300A1 (en) * 2002-11-25 2005-09-29 Chiron Corporation Methods for treating cancer using Porimin as a target
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
KR20120108967A (ko) 2009-09-16 2012-10-05 제넨테크, 인크. 코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도
EP2824111B1 (en) * 2010-04-30 2017-03-22 Alexion Pharmaceuticals, Inc. Anti-C5A Antibodies and Methods for Using the Antibodies
US10851178B2 (en) * 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
SG11201508732PA (en) * 2013-04-25 2015-11-27 Scripps Korea Antibody Inst Method for refining protein including self-cutting cassette and use thereof
RS61907B1 (sr) 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena
KR102095096B1 (ko) * 2015-08-26 2020-03-30 바이슨 테라퓨틱스 인크. 다중특이적 항체 플랫폼 및 관련 방법

Also Published As

Publication number Publication date
JP2024023264A (ja) 2024-02-21
AU2019265699A1 (en) 2021-01-07
MX2020011844A (es) 2021-04-13
US20220089756A1 (en) 2022-03-24
AU2019265699B2 (en) 2026-03-12
EP3790904A1 (en) 2021-03-17
JP7785734B2 (ja) 2025-12-15
AU2026201242A1 (en) 2026-04-23
JP2021523101A (ja) 2021-09-02
CA3099450A1 (en) 2019-11-14
MX2025001939A (es) 2025-04-02
US12384849B2 (en) 2025-08-12
US20250197518A1 (en) 2025-06-19
WO2019217587A1 (en) 2019-11-14
JP2026035775A (ja) 2026-03-04

Similar Documents

Publication Publication Date Title
IL290412A (en) Novel cd47 monoclonal antibodies and uses thereof
MA52742A (fr) Anticorps bispécifiques dll3-cd3
EP3784699A4 (en) OPTIMIZED ANTI-TL1A ANTIBODIES
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
MA50505A (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
IL268620A (en) Anti-lag3 antibodies
EP3898698A4 (en) ANTIBODIES SPECIFIC TO MUC18
EP3822289A4 (en) ANTI-SIRP-ALPHA ANTIBODIES
MA49038A (fr) Anticorps bispécifiques se liant particulièrement à pd1 et lag3
EP3693390A4 (en) SPECIFIC ANTIBODIES AGAINST CD47 AND PD-L1
IL279894A (en) Antibodies binding to ilt4
EP3883970A4 (en) ANTI-B7-H3 ANTIBODIES
MA45784A (fr) Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps
EP3589313A4 (en) ANTI-TIGITE ANTIBODY
MX2017007247A (es) Receptor acoplado a la proteina g dirigida a anticuerpos y metodos de uso.
MA47268A (fr) Anticorps anti-gpc3
EP3507307A4 (en) BISPECIFIC ANTIBODIES
EP3441086A4 (en) MONOCLONAL ANTI-PD-1 ANTIBODY
MA40901A (fr) Anticorps bispécifiques anti-tnf/anti-il-3
EP3752536A4 (en) ANTI-HER2 ANTIBODIES
EP3617231A4 (en) ANTI-GPC-1 ANTIBODY
MA52152A (fr) Anticorps
EP3626745A4 (en) RECOMBINANT BISPECIFIC ANTIBODY
EP3746120A4 (en) ANTI-PD-1 ANTIBODY